This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Academic Highlights

Guidelines for the Use of Long-Acting Injectable Atypical Antipsychotics.

John M. Kane, MD, Robert R. Conley, MD, Samuel J. Keith, MD, Henry A. Nasrallah, MD, and Martin Turner, MB, BS

Published: January 1, 2004

Article Abstract

Click to enlarge page

John M. Kane, M.D., opened the meeting by addressing the need for guidelines on the use of long-acting injectable atypical antipsychotics. For about 40 years, some of the conventional antipsychotics, which include chlorpromazine, fluphenazine, and haloperidol, have been available in long-acting injectable formulations for the long-term treatment of schizophrenia. In 1989, clozapine became the first atypical antipsychotic to be approved by the U.S. Food and Drug Administration (FDA). However, until recently, none of the atypical antipsychotics which also include aripiprazole, olanzapine, quetiapine, risperidone, andziprasidonehave been available in injectable formulations.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 65

Quick Links: